Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

DSpace Repository

Show simple item record

dc.contributor.author Arendt, Anne-Marie
dc.contributor.author Heubach, Florian
dc.contributor.author Maier, Claus-Philipp
dc.contributor.author Jung, Gundram
dc.contributor.author Kowalewski, E.
dc.contributor.author Rabsteyn, Armin
dc.contributor.author Amorelli, Germano
dc.contributor.author Seitz, Christian
dc.contributor.author Schlegel, Paul Martin
dc.contributor.author Handgretinger, Rupert
dc.contributor.author Lang, Peter
dc.date.accessioned 2024-04-18T08:19:00Z
dc.date.available 2024-04-18T08:19:00Z
dc.date.issued 2023
dc.identifier.issn 0340-7004
dc.identifier.uri http://hdl.handle.net/10900/152876
dc.language.iso en en
dc.publisher New York : Springer de_DE
dc.relation.uri http://dx.doi.org/10.1007/s00262-023-03536-x
dc.subject.ddc 610 de_DE
dc.subject.ddc 570 de_DE
dc.title Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3) de_DE
dc.type Article de_DE
utue.quellen.id 20240124000000_01114
utue.publikation.seiten 3813-3824 de_DE
utue.personen.roh Arendt, A. -M.
utue.personen.roh Heubach, F.
utue.personen.roh Maier, C. P.
utue.personen.roh Giardino, S.
utue.personen.roh Jung, G.
utue.personen.roh Kowalewski, E.
utue.personen.roh Rabsteyn, A.
utue.personen.roh Amorelli, G.
utue.personen.roh Seitz, C.
utue.personen.roh Schlegel, P.
utue.personen.roh Handgretinger, R.
utue.personen.roh Lang, P.
dcterms.isPartOf.ZSTitelID Cancer Immunology Immunotherapy de_DE
dcterms.isPartOf.ZS-Issue 11 de_DE
dcterms.isPartOf.ZS-Volume 72 de_DE
utue.fakultaet 04 Medizinische Fakultät
utue.fakultaet 07 Mathematisch-Naturwissenschaftliche Fakultät
utue.fakultaet Sonstige


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record